-+ 0.00%
-+ 0.00%
-+ 0.00%

T-MAXIMUM B7-H3-TARGETED ALLOGENEIC CAR-T THERAPY MT027 RECEIVES FDA FAST TRACK DESIGNATION, ACCELERATING GLOBAL DEVELOPMENT FOR INTRACRANIAL SOLID TUMORS

Reuters·08/31/2026 12:00:28

Please log in to view news